[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2013006670A - Derivado de 2-carboxamida-4-piperazinil-benzofurano. - Google Patents

Derivado de 2-carboxamida-4-piperazinil-benzofurano.

Info

Publication number
MX2013006670A
MX2013006670A MX2013006670A MX2013006670A MX2013006670A MX 2013006670 A MX2013006670 A MX 2013006670A MX 2013006670 A MX2013006670 A MX 2013006670A MX 2013006670 A MX2013006670 A MX 2013006670A MX 2013006670 A MX2013006670 A MX 2013006670A
Authority
MX
Mexico
Prior art keywords
carboxamide
piperazinyl
benzofuran derivative
compound
benzofuran
Prior art date
Application number
MX2013006670A
Other languages
English (en)
Inventor
Helena Gybaeck
Jonas Malmstroem
Elgaard Gitte Terp
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2013006670A publication Critical patent/MX2013006670A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

La presente invención se relaciona con un compuesto de la fórmula (I), y a composiciones farmacéuticas, que contienen el compuesto y al uso del compuesto en terapia, por ejemplo en tratar trastornos cognitivos, así como a intermediarios útiles en la preparación de los mismos.
MX2013006670A 2010-12-20 2011-12-19 Derivado de 2-carboxamida-4-piperazinil-benzofurano. MX2013006670A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424944P 2010-12-20 2010-12-20
PCT/SE2011/051535 WO2012087229A1 (en) 2010-12-20 2011-12-19 2-carboxamide-4-piperazinyl-benzofuran derivative

Publications (1)

Publication Number Publication Date
MX2013006670A true MX2013006670A (es) 2013-07-29

Family

ID=46314244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006670A MX2013006670A (es) 2010-12-20 2011-12-19 Derivado de 2-carboxamida-4-piperazinil-benzofurano.

Country Status (11)

Country Link
US (1) US9012457B2 (es)
EP (1) EP2655365B1 (es)
JP (1) JP5847194B2 (es)
KR (1) KR20130132932A (es)
CN (1) CN103380129B (es)
AU (1) AU2011345381A1 (es)
CA (1) CA2821480A1 (es)
MX (1) MX2013006670A (es)
RU (1) RU2013131161A (es)
WO (1) WO2012087229A1 (es)
ZA (1) ZA201303887B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013006670A (es) 2010-12-20 2013-07-29 Astrazeneca Ab Derivado de 2-carboxamida-4-piperazinil-benzofurano.
CN105636581A (zh) * 2013-12-03 2016-06-01 豪夫迈·罗氏有限公司 药物组合物
DK3548463T3 (da) 2016-12-05 2020-11-30 Bayer Cropscience Ag Fremgangsmåde til fremstilling af 3-substituerede 2-vinylphenylsulfonater

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3571436D1 (en) * 1984-12-21 1989-08-17 Duphar Int Res New pharmaceutical compositions having anti-psychotic properties
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
EP1007523B9 (en) 1997-07-25 2004-09-08 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
JP2002531498A (ja) 1998-12-04 2002-09-24 ニューロサーチ、アクティーゼルスカブ イオンチャネル活性剤としてのイサチン誘導体の使用方法
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
DE10041574A1 (de) * 2000-08-24 2002-03-07 Merck Patent Gmbh Chromenonderivate
ES2268113T3 (es) 2001-06-15 2007-03-16 F. Hoffmann-La Roche Ag Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6.
BR0312446A (pt) 2002-06-10 2005-04-19 Bayer Healthcare Ag 2-heteroaril carboxamidas
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
WO2005077885A1 (en) 2004-02-06 2005-08-25 Yale University Ruthenium-catalyzed hydroamination of olefins
WO2006062481A1 (en) 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
WO2007053093A1 (en) 2005-11-04 2007-05-10 Astrazeneca Ab Chroman compounds as 5 ht1b antagonists
AR059356A1 (es) 2006-02-14 2008-03-26 Astrazeneca Ab Nuevos radioligandos
EP2094686A1 (en) * 2006-09-26 2009-09-02 Glaxo Group Limited 5-{2-[4-(2-methyl-5-quinolinyl)-l-piperidinyl]ethyl} quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairement, psychotic disorders, anxiety, depression, etc.
WO2008055808A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
US8367676B2 (en) 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774
MX2013006670A (es) 2010-12-20 2013-07-29 Astrazeneca Ab Derivado de 2-carboxamida-4-piperazinil-benzofurano.

Also Published As

Publication number Publication date
JP2014500310A (ja) 2014-01-09
WO2012087229A1 (en) 2012-06-28
EP2655365A1 (en) 2013-10-30
KR20130132932A (ko) 2013-12-05
RU2013131161A (ru) 2015-01-27
AU2011345381A1 (en) 2013-06-13
US9012457B2 (en) 2015-04-21
JP5847194B2 (ja) 2016-01-20
EP2655365B1 (en) 2015-12-16
EP2655365A4 (en) 2014-08-13
ZA201303887B (en) 2014-03-26
CN103380129A (zh) 2013-10-30
US20140329830A1 (en) 2014-11-06
CN103380129B (zh) 2016-04-20
CA2821480A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
IN2014MN00988A (es)
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
NZ608116A (en) Triazine-oxadiazoles
MX343706B (es) Derivados heterocíclicos novedosos.
IN2015DN01119A (es)
MY148948A (en) Catecholamine derivatives and prodrugs thereof
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
TN2014000112A1 (en) Ep1 receptor ligands
GEP201706621B (en) Benzamides
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX364400B (es) Compuestos de tetraciclina.
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators
IN2012DN01292A (es)
IN2013DN02555A (es)
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal